• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For HCA Healthcare Stock Could Change Following Revenue Beat

    Simply Wall St·11/01/2026 20:31:07
    语音播报
    • HCA Healthcare reported third quarter 2026 sales of US$19,849 million and net income of US$1,579 million, alongside higher diluted EPS from continuing operations of US$7.27, and affirmed a US$0.78 quarterly dividend while continuing sizable share repurchases.
    • The mix of higher insured patient volumes, flat year to date net income, and aggressive capital returns through dividends and buybacks highlights how HCA Healthcare is balancing operating pressures with shareholder payout priorities.
    • The focus now turns to how this earnings result, driven by stronger insured volumes, could influence HCA Healthcare's broader investment narrative.

    Scan beyond HCA Healthcare and identify other hospital and insurer exposed stocks that combine resilient earnings power with disciplined capital returns by using the curated 29 resilient stocks with low risk scores.

    HCA Healthcare Investment Narrative Recap

    To own HCA Healthcare, you need to be comfortable with a hospital operator that relies on insured volume growth and tight cost control to offset payer mix and reimbursement headwinds. The third quarter update fits that picture. Revenue rose year on year while net income for both the quarter and year to date stayed broadly similar, so the core story did not change.

    The near term swing factor is whether insured patient volumes and cost discipline can outweigh the shift toward more uninsured patients as exchange coverage rolls off. The biggest risk remains policy driven coverage changes and Medicaid funding resets that could pressure margins if payer mix weakens faster than HCA Healthcare can cut costs.

    The share repurchase update from July to September is particularly relevant for investors who focus on how HCA Healthcare’s earnings power translates into per share metrics. The company retired 7,230,000 shares in the third quarter for US$2,970m, and has completed 13,610,436 shares repurchased year to date for US$5,759.57m under the January 2026 program.

    This level of buyback activity means relatively flat net income can still translate into higher diluted EPS, as reflected in US$7.27 in the third quarter and US$22.05 for the first nine months. For shareholders, the key operational drivers remain insured volume resilience and cost programs, with capital returns such as these buybacks amplifying the impact but not changing the underlying coverage and procedure mix risks.

    HCA Healthcare’s current earnings are US$6.8b, and analysts see that rising to US$7.1b by 2029. This implies an earnings increase of about US$0.3b, based on forecast revenue growth of 4.3% a year and projected 2029 revenues of US$88.5b.

    Uncover why HCA Healthcare's fair value indicates that HCA Healthcare is in line with its current price.

    NYSE:HCA 1-Year Stock Price Chart
    NYSE:HCA 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts focus on HCA Healthcare’s capital spending as a potential upside catalyst. They were pencilling in 4.9% annual revenue growth and earnings of about US$7.7b by 2029 before this quarter’s results and the latest dividend and buyback update. You can use this new information to test how far your view lines up with those more bullish forecasts or whether it leads you toward a different narrative entirely.

    Explore 3 other HCA Healthcare fair value estimates, including one that suggests as much as 85% upside from the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking for more HCA Healthcare investment ideas?

    If this HCA Healthcare update has sharpened your thinking, it can help to widen the lens and compare it with other businesses that share some of the same traits. Use the Simply Wall St Screener to line up peers by quality, income potential, and balance sheet strength so you can see where HCA Healthcare fits in your broader watchlist.

    • For investors who want resilience first, filter for companies with lower risk scores through the 29 resilient stocks with low risk scores and see which ones earn a spot beside HCA Healthcare in your portfolio.
    • If value is your priority, check stocks that pair strong fundamentals with what may be conservative market expectations via the 33 high quality undervalued stocks and compare their profiles to HCA Healthcare.
    • For readers building around reliable income, scan for higher yielding payers with robust cash flows using the 5 dividend fortresses and assess how they stack up next to HCA Healthcare on payouts and balance sheet support.